Review Article
Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS
Table 1
Evidence for protective effects of Nrf2-activation in animal models of neurodegenerative disorders.
| Disease | Animal model | Method of Nrf2-activation | Reference |
| ALS | G93A-SOD1 mice | Synthetic triterpenoids (CDDO-ethylamide (CDDO-EA), CCDO-trifluoroethylamide (CDDO-TFEA)) | Neymotin et al., 2011 [29] | Alzheimer’s disease (AD) | Intracerebroventricular infusion of Abeta peptides in rats | Curcumin | Frautschy et al., 2001 [30] | AD | Transgenic APP/PS1 mice | Tert-butylhydroquinone/adenoviral Nrf2 gene transfer | Kanninen et al., 2008 [31] | AD | Transgenic 19959 mice | CDDO-methylamide (CDDO-MA) | Dumont et al., 2009 [32] | AD | Transgenic APP/PS1 mice | Intrahippocampal injection of Nrf2-expressing lentiviral vector | Kanninen et al., 2009 [33] | Parkinson’s disease (PD) | MPTP-toxicity (mice)
| Tert-butylhydroquinone | Abdel-Wahab, 2005 [34] | PD | MPTP-toxicity (mice) 3-NP-toxicity (rats) | CDDO-MA | Yang et al., 2009 [35] | PD | MPTP-toxicity (mice) | Astrocytic Nrf2-overexpression | Chen et al., 2009 [36] | PD | Alpha-synuclein expressing Drosophila | Nrf2-overexpression, Keap1-downregulation | Barone et al., 2011 [37] | Huntington’s disease (HD) | Transgenic N171-82Q mice | CDDO-EA, CDDO-TFEA | Stack et al., 2010 [38] | HD | CAG 140 knock in mice | Curcumin | Hickey et al., 2012 [39] |
|
|